In our analysis, it estimated that compared with chemotherapy, nivolumab plus ipilimumab was cost-effective in advanced NSCLC patients with PD-L1 ≥ 50% and PD-L1 ≥ 1% but not in the PD-L1 <1% populations at a WTP threshold of $150,000 per QALY. This evidence concerns the gene CD274 and non-small cell lung carcinoma.